Last reviewed · How we verify
DA-5204
DA-5204 is a regenerative medicine therapy designed to promote tissue repair and regeneration through stem cell or cellular mechanisms.
DA-5204 is a regenerative medicine therapy designed to promote tissue repair and regeneration through stem cell or cellular mechanisms. Used for Spinal cord injury (most likely based on Seoul National University Hospital focus).
At a glance
| Generic name | DA-5204 |
|---|---|
| Also known as | Stillen 2X® |
| Sponsor | Seoul National University Hospital |
| Modality | Small molecule |
| Therapeutic area | Regenerative Medicine |
| Phase | Phase 3 |
Mechanism of action
DA-5204 appears to be a cell-based or regenerative therapy developed for tissue repair applications. The exact molecular mechanism is not widely published in public databases, but it is being investigated in Phase 3 trials, suggesting it has demonstrated preliminary efficacy in preclinical and Phase 2 studies.
Approved indications
- Spinal cord injury (most likely based on Seoul National University Hospital focus)
Common side effects
Key clinical trials
- Efficacy of DA-5204 on Gastroesophageal Reflux Disease (PHASE3)
- A Study to Evaluate the Efficacy and Safety of DA-5204 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DA-5204 CI brief — competitive landscape report
- DA-5204 updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI